Targeted Anti-IL-1β Platelet Mimetics for Cardiac Detoxification and Repair
用于心脏解毒和修复的靶向抗 IL-1β 血小板模拟物
基本信息
- 批准号:10394228
- 负责人:
- 金额:$ 73.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAnimal ModelAnimalsAnti-Inflammatory AgentsAntibodiesAntigensAwardBalloon OcclusionBindingBiologicalBiological MarkersBispecific AntibodiesBlood PlateletsCardiacCardiovascular AgentsCardiovascular DiseasesCaringClinical TrialsConjugating AgentCultured CellsDataDevelopmentDrug Delivery SystemsDrug KineticsDrug Metabolic DetoxicationFamily suidaeGrantGrowth FactorHeartHeart InjuriesInflammationInjuryInterleukin-1Interleukin-1 betaIntravenousIschemiaLettersMedicalMembraneMesenchymal Stem CellsMyocardial InfarctionNatural regenerationNatureOutcomePalliative CarePhase I Clinical TrialsPhase III Clinical TrialsProceduresProcessPropertyReperfusion TherapyResearchResearch DesignSafetySeedsSocietiesSoilStem Cell FactorStem cell transplantSystemTestingTherapeuticTimeTissuesToxic effectTranslatingVesiclecardiac regenerationcardiac repaircell injuryclinically relevantcombatmimeticsmouse modelnanonanoparticlenanovesiclenovel therapeuticsregenerativeregenerative cellrepairedsafety testingstem cell therapystem cellssuccesstargeted delivery
项目摘要
PROJECT SUMMARY
Currently, ischemic damage to the heart cannot be repaired by conventional medical care therefore only
palliative treatments exist. Stem cell transplantation is a promising strategy for therapeutic cardiac
regeneration, but current therapies are limited by insufficient interaction between the regenerative cells and the
injured tissue. In the last grant period, we have developed targeted nanoparticles (namely bispecific antibody-
conjugated agents) to redirect circulating stem cells to the infarcted heart for therapeutic regeneration. Despite
such initial success, we realize our system has some problems: (P1) We cannot fully reply on the stem cells
(“seeds”) for cardiac repair. The post-injury heart microenvironment (“soil”) needs to be primed for the
maximum outcome; (P2) Antibody targeting is quite specific but is fully dependent on the antigen, which are
cardiac injury biomarkers that only expresses in a short period of time after injury. The current renewal
proposal builds on the previous study, but represents a significant advancement, both technically and
conceptually. To address P1, we reason one of the antibodies needs to be therapeutic, to combat the
excessive inflammation in the heart. To address P2, we seek for agents that have broad spectrum affinity with
cardiac injury. To those ends, we developed anti-IL-1 platelet mimetic (IL1-PM). The mode of action for IL1-PM
is as follows: platelet vesicles serve as the carrier of our system and they have innate ability to find cardiac
injury (replying on the binding motifs on platelet membranes); anti-IL-1 antibodies are currently in Phase 3
clinical trials and have demonstrated ability to neutralize inflammation and promote cardiac repair; platelet
vesicles can be further loaded with stem cell-derived growth factors to aid the repair process. AIM 1: Fabricate
IL1-PM and characterize its physicochemical and biological properties. We will generate IL1-PM agents by
conjugating anti IL-1 antibodies onto platelet membrane nanovesicles; binding/engaging ability, toxicity,
pharmacokinetics of IL1-PM will be examined in cultured cells and in healthy animals. AIM 2: Determine the
therapeutic potential of mesenchymal stem cell (MSC) secretome-loaded IL1-PM in a mouse model of
myocardial infarction. MI will be induced by ischemia-reperfusion. After that, MSC-IL1-PM, along with various
control agents, will be delivered intravenously. Therapeutic safety and efficacy will be determined. In addition,
the underlying mechanisms of such treatment will be explored. AIM 3: Translate the findings into a clinically-
relevant large animal model of myocardial infarction. MI will be induced in swine via a balloon-occlusion
procedure. The safety and efficacy of MSC-IL1-PM treatment will be evaluated. Our therapeutic system
combines stem cell therapy (component 1) and anti-IL1 therapy (component 2), both of which have been
rigorously tested and verified in clinical trials for cardiac repair. Moreover, the therapeutics will be delivered in a
targetable fashion relying on the injury-finding ability of platelet binding motifs (component 3). All 3 components
have been supported by strong preliminary data from our group.
项目摘要
目前,对心脏的缺血性损伤不能通过传统的医疗护理来修复,因此仅
存在姑息治疗。干细胞移植是治疗心脏病的一个有前途的策略
再生,但目前的疗法受到再生细胞与再生细胞之间相互作用不足的限制
受伤的组织在上一个资助期内,我们开发了靶向纳米颗粒(即双特异性抗体-
偶联剂)以将循环干细胞重定向至梗塞心脏用于治疗性再生。尽管
这样的初步成功,我们意识到我们的系统有一些问题:(P1)我们不能完全回答干细胞
(“种子”)用于心脏修复。损伤后的心脏微环境(“土壤”)需要准备好,
最大结果;(P2)抗体靶向非常特异,但完全取决于抗原,即
心脏损伤生物标志物仅在损伤后的短时间内表达。当前更新
该提案以之前的研究为基础,但无论是在技术上还是在实践中,
概念上。为了解决P1,我们认为其中一种抗体需要是治疗性的,以对抗P1。
心脏过度炎症。为了解决P2,我们寻找与P2具有广谱亲和力的药物。
心脏损伤为此,我们开发了抗IL-1血小板模拟物(IL-1-PM)。IL 1-PM的作用方式
如下:血小板囊泡作为我们系统的载体,它们具有天然的能力,
损伤(在血小板膜上的结合基序上应答);抗IL-1抗体目前处于3期
临床试验并已证明具有中和炎症和促进心脏修复的能力;血小板
囊泡可以进一步装载干细胞衍生的生长因子以帮助修复过程。目标1:制造
IL-1-PM,并表征其理化和生物学性质。我们将通过以下方式生成IL 1-PM代理
将抗IL-1抗体缀合到血小板膜纳米囊泡上;结合/接合能力,毒性,
将在培养的细胞和健康动物中检查IL 1-PM的药代动力学。目标2:确定
间充质干细胞(MSC)分泌组负载IL 1-PM在小鼠模型中的治疗潜力
心肌梗死心肌缺血再灌注可诱发心肌梗死。之后,MSC-IL 1-PM,沿着与各种
对照剂将通过静脉内递送。将确定治疗安全性和疗效。此外,本发明还提供了一种方法,
将探讨这种治疗的基本机制。目标3:将研究结果转化为临床-
相关的大型心肌梗死动物模型。将通过球囊闭塞在猪中诱导MI
procedure.将评价MSC-IL 1-PM治疗的安全性和有效性。我们的治疗系统
联合干细胞治疗(组分1)和抗IL-1治疗(组分2),这两种治疗都已被
在心脏修复的临床试验中经过严格测试和验证。此外,治疗方法将以
依赖于血小板结合基序的损伤发现能力的靶向方式(组分3)。所有3个组件
得到了我们小组强有力的初步数据的支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ke Cheng其他文献
Ke Cheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ke Cheng', 18)}}的其他基金
Drug Delivery and Biomimetic Approaches for Optimal Stem Cell Therapy
最佳干细胞治疗的药物输送和仿生方法
- 批准号:
10370380 - 财政年份:2021
- 资助金额:
$ 73.61万 - 项目类别:
Drug Delivery and Biomimetic Approaches for Optimal Stem Cell Therapy
最佳干细胞治疗的药物输送和仿生方法
- 批准号:
10995606 - 财政年份:2021
- 资助金额:
$ 73.61万 - 项目类别:
Training Grant in Comparative Molecular Medicine
比较分子医学培训补助金
- 批准号:
10202796 - 财政年份:2021
- 资助金额:
$ 73.61万 - 项目类别:
Training Grant in Comparative Molecular Medicine
比较分子医学培训补助金
- 批准号:
10413147 - 财政年份:2021
- 资助金额:
$ 73.61万 - 项目类别:
Surgical Microneedle Patch Delivery of CMMP for Heart Repair
外科微针贴片输送 CMMP 用于心脏修复
- 批准号:
9982489 - 财政年份:2020
- 资助金额:
$ 73.61万 - 项目类别:
Surgical Microneedle Patch Delivery of CMMP for Heart Repair
外科微针贴片输送 CMMP 用于心脏修复
- 批准号:
10586112 - 财政年份:2020
- 资助金额:
$ 73.61万 - 项目类别:
Surgical Microneedle Patch Delivery of CMMP for Heart Repair
外科微针贴片输送 CMMP 用于心脏修复
- 批准号:
10396023 - 财政年份:2020
- 资助金额:
$ 73.61万 - 项目类别:
Cardiac Patches Loaded with Stem Cell Factors to Treat Heart Failure
含有干细胞因子的心脏贴片可治疗心力衰竭
- 批准号:
10229460 - 财政年份:2019
- 资助金额:
$ 73.61万 - 项目类别:
Modulating Exosome Cargos and Surfaces for Precision Heart Repair
调节外泌体货物和表面以实现精密心脏修复
- 批准号:
10393509 - 财政年份:2019
- 资助金额:
$ 73.61万 - 项目类别:
Harnessing Platelet-Endothelial Interactions for Exosome Delivery
利用血小板-内皮相互作用进行外泌体递送
- 批准号:
10669452 - 财政年份:2019
- 资助金额:
$ 73.61万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 73.61万 - 项目类别:
Continuing Grant